Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF and Angiotensin-II Response to HCG in PCOS
NCT02265861Phase 1Completed
- Sponsor
- Nanjing University School of Medicine
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of human chorionic gonadotropin in polycystic ovary syndrome (PCOS) (4 arms), sponsored by Nanjing University School of Medicine. Primary endpoints: Vascular Endothelial Growth Factor at 24 hours and Angiotensin-II at 24 hours. Started Jan 2010; status: completed.
02
Drugs
human chorionic gonadotropin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT02265861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265861.